Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

33
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
33
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

38
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
38
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

36
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
36
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

28
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
28
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

743
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
743

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exercise training for cardiovascular prevention in patients with cancer.

European heart journal·2026
Same author

Interaction between GRASP-HF and ICARe-HF: a strategic alliance to improve heart failure care in Europe and beyond.

European heart journal. Quality of care & clinical outcomes·2026
Same author

European Society of Cardiology updated curriculum for heart failure nurses: developed by the Heart Failure Association, in collaboration with the Association of Cardiovascular Nurses and Allied Professions of the European Society of Cardiology.

European journal of heart failure·2026
Same author

Circulating metabolomic and lipidomic profiles distinguish patients with acute heart failure de novo vs. worsening of heart failure.

Polish archives of internal medicine·2026
Same author

Worsening renal function in acute heart failure: a hemoconcentration-conditioned interpretation with ranges of benefit, safety, and harm.

Revista espanola de cardiologia (English ed.)·2026
Same author

Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

European journal of heart failure·2026

Related Experiment Video

Updated: Sep 17, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.3K

Guideline-Directed Medical Therapy Use in the STRONG-HF Trial.

Xiang Zhang1, Beth Davison2,3,4, Marianna Adamo5

  • 1Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada (X.Z., J.A.E.).

Circulation. Heart Failure
|July 3, 2025
PubMed
Summary

A new GDMT intensity score effectively measures heart failure medication use and is linked to improved clinical outcomes. This standardized approach offers a comprehensive assessment beyond traditional trial methods.

Keywords:
clinical trialguideline directed medical therapyheart failure

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.6K

Related Experiment Videos

Last Updated: Sep 17, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.3K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.6K

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Assessing medication changes in heart failure (HF) trials is complex and may not fully represent patient care.
  • A need exists for a comprehensive and standardized method to evaluate guideline-directed medical therapies (GDMT) in HF.
  • The STRONG-HF trial provides a platform to assess GDMT intensity and its association with clinical outcomes.

Purpose of the Study:

  • To evaluate the utility of a GDMT intensity score for assessing medication use in heart failure patients.
  • To examine the association between GDMT intensity score and clinical outcomes in the STRONG-HF trial.
  • To compare GDMT adherence and intensity between usual care and high-intensity care strategies.

Main Methods:

  • Utilized data from the STRONG-HF trial, including baseline and follow-up assessments.
  • Applied a GDMT intensity score to evaluate medication use and adherence (basic, indication-corrected, dose-corrected).
  • Correlated GDMT intensity score with clinical outcomes up to 180 days post-intervention.

Main Results:

  • High-intensity care significantly increased triple therapy indication-corrected and dose-corrected use compared to usual care at 90 days (P<0.001).
  • At 90 days, 88.4% of patients in the high-intensity arm achieved a GDMT intensity score >7 versus 14.3% in the usual care arm (P<0.0001).
  • The GDMT intensity score at baseline and 90 days was correlated with improved clinical outcomes at 180 days.

Conclusions:

  • The GDMT intensity score offers a standardized and comprehensive measure of medication use in heart failure.
  • This score is significantly associated with clinical outcomes, highlighting its prognostic value.
  • The GDMT intensity score should be considered as a potential trial endpoint in future heart failure studies.